Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Inhibitor Therapeutics, Inc. (INTI) had Return on Tangible Equity of 255.46% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-3.30M |
|
-- |
|
-- |
|
$3.43M |
|
$-3.43M |
|
$0.13M |
|
$-3.30M |
|
$-3.30M |
|
$-3.30M |
|
$-3.30M |
|
$-3.30M |
|
$-3.30M |
|
$-3.43M |
|
$-3.43M |
|
172.51M |
|
172.51M |
|
$-0.02 |
|
$-0.02 |
|
| Balance Sheet Financials | |
$2.45M |
|
-- |
|
$0.06M |
|
$2.51M |
|
$0.77M |
|
-- |
|
$3.04M |
|
$3.80M |
|
$-1.29M |
|
$-1.29M |
|
$-1.29M |
|
172.57M |
|
| Cash Flow Statement Financials | |
$-3.23M |
|
-- |
|
-- |
|
$5.61M |
|
$2.38M |
|
$-3.23M |
|
$0.02M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.19 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.23M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
255.46% |
|
|
Return on Tangible Equity |
255.46% |
-131.42% |
|
255.46% |
|
$-0.01 |
|
$-0.02 |
|
$-0.02 |
|